Perazolin (sobuzoxane) / Zenyaku Holdings - LARVOL DELTA

Sobuzoxane Combo Extends Survival in Elderly DLBCL Group (Cancer Network) - "Sobuzoxane plus etoposide and rituximab may be safe and effective in a subgroup of elderly patients with diffuse large B-cell lymphoma and low tumor burden....At a median follow-up of 35.7 months (range, 9.3-93.8), the median progression-free survival (PFS) was 17.2 months (95% CI, 7.4-44.4), the 2-year PFS rate was 44% (95% CI, 24%-62%), and the 5-year PFS rate was 22.6% (95% CI, 6.6%-44.3%). The median overall survival (OS) was 32.0 months (95% CI, 16.2-not reached [NR]), the 2-year OS rate was 62% (95% CI, 42%-77%), and the 5-year OS rate was 31.7% (95% CI, 13.4%-51.8%)."

Retrospective data • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology